Pain improvement (assessed as improvement from 1 major category to next) · women with primary dysmenorrhoea
Combined OCP may leads to higher pain improvement (assessed as improvement from 1 major category to… compared with placebo or no treatment (low certainty).
1 finding from 1 review
Adverse events · women with primary dysmenorrhoea
Combined OCP probably leads to higher adverse events compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Requirement for additional medication · women with primary dysmenorrhoea
Combined OCP may leads to lower requirement for additional medication compared with placebo or no treatment (low certainty).
1 finding from 1 review
Time off school or work · women with primary dysmenorrhoea
Combined OCP may leads to lower absence from work or school compared with placebo or no treatment (low certainty).
1 finding from 1 review
Stress symptoms ( · healthcare workers
3 findings from 1 review
no estimate extracted
41 studies · 3645 participants
Low
no estimate extracted
19 studies · 1851 participants
Low
no estimate extracted
1 study · 68 participants
Very low
Stress symptoms ( · healthcare workers
3 findings from 1 review
no estimate extracted
35 studies · 2366 participants
Low
no estimate extracted
6 studies · 427 participants
Low
no estimate extracted
0 studies · 0 participants
GRADE not reported
Depression: meeting study criteria for depression at end of · people with depression after stroke
It is very uncertain whether pharmacological interventions changes depression: meeting study criteria for depression at end of… compared with placebo (very low certainty).
2 findings from 1 review
Depression: < 50% reduction in scale scores at end of treatment (primary outcome) · people with depression after stroke
It is very uncertain whether pharmacological interventions changes depression: < 50% reduction in scale scores at end of treatment… compared with placebo (very low certainty).
1 finding from 1 review
Depression: mean scores at end of treatment (secondary outcome) · people with depression after stroke
1 finding from 1 review
Adverse events: death ‐ at end of treatment (secondary outcome) · people with depression after stroke
It is very uncertain whether pharmacological interventions changes adverse events: death (secondary outcome) compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects (central nervous system) · people with depression after stroke
It is very uncertain whether pharmacological interventions changes adverse events: all ‐ central nervous system events (e.g. confusion,… compared with placebo (very low certainty).
1 finding from 1 review
Gastrointestinal adverse events · people with depression after stroke
It is very uncertain whether pharmacological interventions changes adverse events: all ‐ gastrointestinal effects (e.g. constipation,… compared with placebo (very low certainty).
1 finding from 1 review
Clinical improvement (dichotomous) · active EoE patients
Corticosteroids may leads to higher clinical improvement (dichotomous) compared with placebo (low certainty).
1 finding from 1 review
Histological improvement (dichotomous) · inactive EoE patients
Corticosteroids probably leads to higher histological improvement (dichotomous) compared with placebo (moderate certainty).
1 finding from 1 review
Clinical improvement (continuous) · inactive EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Histological improvement (dichotomous) · inactive EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Histological improvement (continuous) · inactive EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic improvement (dichotomous) · inactive EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic improvement (continuous) · inactive EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · inactive EoE patients
It is very uncertain whether leukotriene receptor antagonist changes withdrawals due to adverse events at 26 weeks compared with placebo (very low certainty).
1 finding from 1 review